NCT00498108View on ClinicalTrials.gov

Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Idiopathic Restless Legs Syndrome
Interventions
DRUG

Rotigotine

Trial Locations (1)

34128

Kassel

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00498108 - Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects | Biotech Hunter | Biotech Hunter